Sotera Health Announces Secondary Offering of Common Stock
Sotera Health (Nasdaq: SHC) has announced a secondary offering of 20 million shares of its common stock. The offering is being conducted by selling stockholders affiliated with Warburg Pincus and GTCR, with Goldman Sachs & Co. LLC serving as the underwriter.
The company itself is not selling any shares and will not receive any proceeds from the offering, although it will cover the offering expenses per its Amended and Restated Registration Rights Agreement. The offering will be made through a prospectus, with a registration statement already filed and effective with the SEC.
Sotera Health (Nasdaq: SHC) ha annunciato un collocamento secondario di 20 milioni di azioni ordinarie. Le azioni saranno vendute da azionisti collegati a Warburg Pincus e GTCR, con Goldman Sachs & Co. LLC come sottoscrittore.
L'azienda non intende vendere azioni né riceverà proventi dall'operazione; tuttavia si farà carico delle spese dell'offerta in base al suo Amended and Restated Registration Rights Agreement. L'offerta sarà effettuata tramite prospetto, e la relativa dichiarazione di registrazione è già stata depositata ed è efficace presso la SEC.
Sotera Health (Nasdaq: SHC) ha anunciado una colocación secundaria de 20 millones de acciones ordinarias. Las acciones serán vendidas por accionistas vinculados a Warburg Pincus y GTCR, con Goldman Sachs & Co. LLC actuando como suscriptor.
La compañía en sí no venderá acciones ni recibirá ingresos por la operación; no obstante, asumirá los gastos de la oferta según su Amended and Restated Registration Rights Agreement. La oferta se realizará mediante un prospecto, y la declaración de registro correspondiente ya fue presentada y es efectiva ante la SEC.
Sotera Health (나스닥: SHC)가 보통주 2,000만 주의 2차 공모를 발표했습니다. 이번 매각은 Warburg Pincus와 GTCR 계열의 매도주주들이 진행하며, 인수업무는 Goldman Sachs & Co. LLC가 맡습니다.
회사는 자체적으로 주식을 판매하지 않으며 공모로부터 수익을 받지 않습니다. 다만 Amended and Restated Registration Rights Agreement에 따라 공모 비용은 부담합니다. 공모는 등록명세서(프로스펙터스)를 통해 이루어지며, 해당 등록신고서는 이미 SEC에 제출되어 효력이 발생했습니다.
Sotera Health (Nasdaq: SHC) a annoncé une offre secondaire de 20 millions d'actions ordinaires. Les actions sont vendues par des actionnaires affiliés à Warburg Pincus et GTCR, avec Goldman Sachs & Co. LLC en tant que souscripteur.
La société elle‑même ne vend pas d'actions et ne recevra aucun produit de l'opération ; elle prendra toutefois en charge les frais de l'offre conformément à son Amended and Restated Registration Rights Agreement. L'offre se fera par prospectus, la déclaration d'enregistrement ayant déjà été déposée et étant en vigueur auprès de la SEC.
Sotera Health (Nasdaq: SHC) hat ein Sekundärangebot von 20 Millionen Aktien seiner Stammaktien angekündigt. Die Aktien werden von veräußernden Aktionären im Zusammenhang mit Warburg Pincus und GTCR verkauft; Goldman Sachs & Co. LLC fungiert als Underwriter.
Das Unternehmen selbst verkauft keine Aktien und wird keine Erlöse aus dem Angebot erhalten, übernimmt jedoch gemäß seiner Amended and Restated Registration Rights Agreement die Kosten des Angebots. Das Angebot erfolgt über einen Prospekt; die zugehörige Registrierungsunterlage wurde bereits bei der SEC eingereicht und ist wirksam.
- None.
- Large secondary offering of 20 million shares could create selling pressure
- Company receiving no proceeds from the offering while bearing the expenses
- Major shareholders (Warburg Pincus and GTCR) reducing their stake in the company
Insights
Private equity firms Warburg Pincus and GTCR are selling 20 million shares in a secondary offering, potentially signaling reduced confidence.
This secondary offering of 20,000,000 shares by Warburg Pincus and GTCR represents a significant development for Sotera Health. To put this in context, these private equity firms are reducing their ownership stakes without the company issuing new shares or receiving any proceeds. The company will, however, bear the expenses of the offering per its Amended and Restated Registration Rights Agreement.
When major institutional investors reduce their positions, it typically signals one of several scenarios: portfolio rebalancing, profit-taking, or reduced confidence in future growth prospects. The market often interprets such moves negatively, as large blocks of shares hitting the market can create temporary selling pressure. The appointment of Goldman Sachs as the sole underwriter suggests a coordinated, controlled distribution of these shares to minimize market disruption.
Investors should note that private equity firms typically have investment timelines and exit strategies built into their models. This offering could simply represent a planned liquidity event rather than a fundamental reassessment of Sotera's prospects. However, the size of the offering relative to the company's float and the timing deserve scrutiny by current shareholders.
What's particularly telling is that the selling is limited to these two private equity backers, with no participation from company insiders or other shareholders, which provides a more nuanced picture of the transaction's significance.
CLEVELAND, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC) (the “Company”) today announced the launch of a secondary offering (the “Offering”) of 20,000,000 shares of its common stock, par value
Goldman Sachs & Co. LLC is acting as the underwriter for the Offering.
The Offering is being made only by means of a prospectus. Copies of the preliminary prospectus relating to the Offering may be obtained, when available, from: Goldman Sachs & Co. LLC, Prospectus Department, 200 West Street, New York, NY 10282, telephone: 1-866-471-2526, facsimile: 212-902-9316 or by email at Prospectus-ny@ny.email.gs.com.
A registration statement relating to these securities was filed with the Securities and Exchange Commission on February 27, 2024, and became effective automatically.
This press release shall not constitute an offer to sell, or the solicitation of an offer to buy these securities, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Forward-looking Statements:
Statements in this press release regarding the Company that are not historical facts are “forward-looking statements” that involve risks and uncertainties. Certain of these risks and uncertainties are described in the Company’s registration statement on Form S-3 filed with the SEC, including under the headings “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements,” under the headings “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in the Company’s most recent Annual Report on Form 10-K. Forward-looking statements made in this release speak only as of the date of this release, and the Company undertakes no obligation to update the information contained in this press release to reflect subsequently occurring events or circumstances, except as required by law.
About Sotera Health:
Sotera Health Company is a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry. Sotera Health goes to market through three businesses – Sterigenics®, Nordion® and Nelson Labs®. Sotera Health is committed to its mission, Safeguarding Global Health®.
INVESTOR RELATIONS CONTACTS:
Jason Peterson
Vice President, Investor Relations and Treasurer, Sotera Health
IR@soterahealth.com
MEDIA CONTACT:
Kristin Gibbs
Chief Marketing Officer, Sotera Health
kgibbs@soterahealth.com
Source: Sotera Health Company
FAQ
How many shares are being offered in Sotera Health's (SHC) secondary offering?
Will Sotera Health (SHC) receive any proceeds from the secondary offering?
Who is underwriting Sotera Health's (SHC) secondary offering?
Who are the selling stockholders in Sotera Health's (SHC) secondary offering?
When did Sotera Health's (SHC) registration statement for this offering become effective?
